|
|
Post by Hot Christian Stocks on Dec 19, 2013 10:23:33 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Dec 20, 2013 7:28:09 GMT -5
$NVLX Nuvilex's Provides Progress Update on Cell Cloning Being Performed by Inno Biologics 2013-12-19 09:30 ET - News Release SILVER SPRING, Md., Dec. 19, 2013 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, provided an update today on the progress made by its contractor, Inno Biologics, regarding the cloning of the cancer-prodrug ifosfamide-activating cells that form the basis for the cancer treatment and will be encapsulated as part of the development of the treatment for Nuvilex's future clinical trials in advanced pancreatic cancer. The cells being cloned at Inno Biologics are those that are able to convert ifosfamide, an anti-cancer prodrug, into its cancer-killing form. Ultimately, the cells obtained will be encapsulated using the Cell-in-a-Box™ cellulose-based live cell encapsulation technology. Together with ifosfamide, the encapsulated cells form Nuvilex's treatment for advanced pancreatic cancer that will be used in the Company's future clinical trials. To date, the cloning process at Inno Biologics has been going well with initial clones that have been isolated using the "State-of-the-Art" Clone-Pix™ technology that allows for optimization of the clone isolation process. The To date, the cloning process at Inno Biologics has been going well with initial clones that have been isolated using the "State-of-the-Art" Clone-Pix™ technology that allows for optimization of the clone isolation process. In addition, a strategic planning meeting was held the week of November 24, 2013 to assess issues regarding the ongoing cloning activities. Participants included Dr. Robert F. Ryan, Nuvilex's Chief Scientific Officer, Datuk Dr. Ahmed Tasir Bin Lope Pihie, CEO of Inno Biologics, Dr. Walter H. Gunzburg, Chairman and Chief Technical Officer of Austrianova and Dr. Brian Salmons, CEO and President of Austrianova from whose company the rights to use the Cell-in-a-Box™ technology for the development of cancer treatments were acquired. In commenting on the cloning process, Dr. Ryan stated, "We are confident with the results of the initial cloning process to this point which showed its capabilities to isolate multiple clones that were grown from single cells. This is critical as we move this project forward to insure the reproducibility of the future cancer treatments being advanced here at Nuvilex. We continue to make progress toward our goal of bringing this treatment option to clinical trials for advanced inoperable pancreatic cancer." www.stockwatch.com/News/Item.aspx?bid=U-z10062059-U%3aNVLX-20131219&symbol=NVLX®ion=U |
|
|
|
Post by Hot Christian Stocks on Jan 12, 2014 22:54:30 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Jan 13, 2014 9:47:23 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Jan 14, 2014 9:39:11 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Jan 15, 2014 9:54:25 GMT -5
$NVLX Nuvilex is currently into its preparations for late-phase clinical trials in advanced, inoperable pancreatic cancer using Cell-in-a-Box, and these trials will only add to the experience the company's executives will have using this technology. Given the solid team they're putting together at MMS, they will likely use that experience to enhance the medical marijuana industry's search for cures to many types of cancer. www.stockwatch.com/News/Item.aspx?bid=U-i1081571-U%3aNVLX-20140114&symbol=NVLX®ion=U |
|
|
|
Post by Hot Christian Stocks on Jan 16, 2014 9:06:33 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Jan 17, 2014 9:37:00 GMT -5
$NVLX – Check out this interview of Nuvilex Upcoming Phase 3 Trials, Study Sites, Study Protocol & More ow.ly/qkcH4 |
|
|
|
Post by Hot Christian Stocks on Jan 21, 2014 8:59:49 GMT -5
Nuvilex, Inc. (OTCQB: NVLX) and a host of marijuana companies are keeping a close eye on what is happening with a petition drive in Florida to get the use of medical marijuana on ballots in time for the November election. Why is Florida important? Well, for a company like Nuvilex and its medical marijuana subsidiary, Marijuana Sciences, Inc., conducting research and developing treatments using the drug are made far easier if the country moves to full acceptance, and Florida could be the domino that sets the last of the states holding out in motion.
|
|
|
|
Post by Hot Christian Stocks on Jan 21, 2014 9:43:28 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Jan 22, 2014 9:54:33 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Jan 22, 2014 10:52:59 GMT -5
$NVLX targeted by Catalysts in the marijuana and medical marijuana industry Baltimore, Maryland - Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, recently published a new research update on Nuvilex Inc. (OTCQB – NVLX). In the update, senior analyst Rob Goldman outlines his latest thesis. "A series of recent landmark events in the marijuana and medical marijuana space, along with a revaluation of biotechs, are set to serve as triggers prompting the accumulation and rise of Nuvilex’s stock back to the levels enjoyed roughly 9 months ago." Nuvilex is a biotechnology company with the rights to a novel cellulose-based live-cell encapsulation technology, called Cell-in-a-BoxTM, that will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. Nuvilex's treatment for pancreatic cancer involves the use of the widely used anticancer prodrug, ifosfamide, together with encapsulated live cells that convert ifosfamide into its active or "cancer-killing" form. Nuvilex's subsidiary, Medical Marijuana Sciences, Inc., is dedicated to the development of cancer treatments based upon the well-known chemical constituents of marijuana. Nuvilex is exploring ways in which the Cell-in-a-BoxTM technology may play a role in these efforts. According to Goldman, the aforementioned triggers include a surge of interest in, and validation of, medical marijuana and the publicly traded firms that operate in the space. Catalysts cited in the research update include a tacit marijuana endorsement by President Obama, which could give a huge shot in the arm to the sector. Plus, given that Colorado’s tax revenue-generating pot shops cannot keep product on the shelves, cash-strapped states and municipalities may view a softening stance on this topic as a tangible opportunity to generate real revenue. In addition, the swift and broad shift in support toward medical marijuana will likely be enhanced during the 2- week Super Bowl marketing period. Since the two participants hail from the states that have legalized marijuana, it is likely that proponents will flood the media with stories on the topic, placing it near the top of the talking points food chain. Finally, Goldman notes that major moves have occurred of late in other anti-cancer stocks while biotech investors seek to find the next biotech slated to move in concert with the launch of upcoming events. With a series of milestone events ahead for the Company, investors could enjoy similar moves as these milestones are achieved, as evidenced by the achievements of its peer group and the subsequent rises in their stock prices. ih.advfn.com/p.php?pid=nmona&article=60756169 |
|
|
|
Post by Hot Christian Stocks on Jan 23, 2014 8:39:08 GMT -5
$NVLX WEALTHMAKERS.COM projected fundamental full valuation of $1.90 per share SILVER SPRING, Md., Jan. 23, 2014 (GLOBE NEWSWIRE) -- WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued a new research report today on Nuvilex, Inc. (OTC:NVLX). The report highlights the short term bullish pattern that has emerged, the SqueezeTrigger Price and the projected fundamental full valuation of $1.90 per share www.stockwatch.com/News/Item.aspx?bid=U-z10065185-U%3aNVLX-20140123&symbol=NVLX®ion=U |
|
|
|
Post by Hot Christian Stocks on Jan 24, 2014 9:37:23 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Jan 26, 2014 21:25:28 GMT -5
$NVLX partner Austrianova will present at the international Phacilitate Cell & Gene Therapy Forum 2014 to be held in Washington, DC January 27-29, 2014 SILVER SPRING, Md., Jan. 24, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that Dr. Walter H. Gunzburg, Chairman and Chief Technical Officer of Nuvilex's partner Austrianova, will present at the international Phacilitate Cell & Gene Therapy Forum 2014 to be held in Washington, DC January 27-29, 2014. Dr. Gunzburg is the co-developer of the novel proprietary and patented cell encapsulation technology that Nuvilex expects will have a profound effect on how cancers and diabetes will be treated in the future. In his presentation, Dr. Gunzburg will present data that will explain the nature of the cellulose-based live-cell encapsulation technology known as Cell-in-a-Box™. In addition to discussing the use of this technology for the encapsulation of stem cells, Dr. Gunzburg will speak to its use as a pivotal part of Nuvilex's treatment for advanced, inoperable pancreatic cancer. Dr. Gunzburg will emphasize the results of earlier Phase 1/2 clinical trials using Nuvilex's treatment for this deadly disease. The worldwide exclusive rights to use the Cell-in-a-Box™ technology in developing treatments for pancreatic and all other forms of cancer, as well as for diabetes, were acquired by Nuvilex from SG Austria Pte. Ltd. (Austrianova) and Austrianova Singapore Pte. Ltd., respectively, in 2013. Nuvilex's proprietary pancreatic cancer treatment consists of the combination of low doses of the well-known anti-cancer prodrug ifosfamide with ifosfamide-activating (convert ifosfamide into its "cancer-killing" form) cells that have been encapsulated using the Cell-in-a-Box™ technology. In Phase 1/2 clinical trials in patients with advanced, inoperable pancreatic cancer, Nuvilex's treatment was shown to essentially double the median survival time and percentage of one-year survivors over those seen in historical data for Gemzar® (gemcitabine), the only drug approved to date by the FDA as a single agent for the treatment of the disease. But unlike Gemzar®, Nuvilex's treatment had no serious treatment-related side effects associated with it. The Phacilitate Cell & Gene Therapy Forum is an international three-day event held annually that focuses on business and strategic issues related to the development of cell therapies and related technologies. It is considered the world's leading strategic and partnering event globally for those in the cell and gene therapy sectors. Sponsors of, and participants in, the event include many of the world's major pharmaceutical and biotech companies. Attendees also include major decision makers from those entities, regulatory personnel and others who join to discuss advances, challenges and opportunities in cell and gene therapy. Commenting on Dr. Gunzburg's appearance at, and participation in, next week's international Cell & Gene Therapy Forum, Nuvilex CEO and President, Kenneth L. Waggoner, commented, "Dr. Gunzburg's research and development of the cellulose-based Cell-in-a-Box™ technology may revolutionize the way many experts view how difficult-to-treat cancers will be managed in the future. We're confident that his presentation and involvement in two panel discussions will capture the imaginations of experts at the Forum. We also strongly believe that the work Dr. Gunzburg and his colleagues have already accomplished, together with research Nuvilex is carrying out itself, via its subsidiary Medical Marijuana Sciences and with potential partners, may result in a sea change in the way many deadly and debilitating diseases are approached and treated in the future." www.stockwatch.com/News/Item.aspx?bid=U-z10065366-U%3aNVLX-20140124&symbol=NVLX®ion=U |
|
